These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 28217962)
1. Synthesis and Pharmacological Evaluation of Identified and Putative Metabolites of the A Holschbach MH; Bier D; Sihver W; Schulze A; Neumaier B ChemMedChem; 2017 May; 12(10):770-784. PubMed ID: 28217962 [TBL] [Abstract][Full Text] [Related]
2. Metabolism of the A(1)1 adenosine receptor positron emission tomography ligand [18F]8-cyclopentyl-3-(3-fluoropropyl)-1-propylxanthine ([18F]CPFPX) in rodents and humans. Bier D; Holschbach MH; Wutz W; Olsson RA; Coenen HH Drug Metab Dispos; 2006 Apr; 34(4):570-6. PubMed ID: 16415116 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of 18F-CPFPX, a novel adenosine A1 receptor ligand: in vitro autoradiography and high-resolution small animal PET. Bauer A; Holschbach MH; Cremer M; Weber S; Boy C; Shah NJ; Olsson RA; Halling H; Coenen HH; Zilles K J Nucl Med; 2003 Oct; 44(10):1682-9. PubMed ID: 14530487 [TBL] [Abstract][Full Text] [Related]
4. New potent A Kreft S; Bier D; Holschbach MH; Schulze A; Coenen HH Nucl Med Biol; 2017 Jan; 44():69-77. PubMed ID: 27821347 [TBL] [Abstract][Full Text] [Related]
5. Synthesis and evaluation of no-carrier-added 8-cyclopentyl-3-(3-[(18)F]fluoropropyl)-1-propylxanthine ([(18)F]CPFPX): a potent and selective A(1)-adenosine receptor antagonist for in vivo imaging. Holschbach MH; Olsson RA; Bier D; Wutz W; Sihver W; Schüller M; Palm B; Coenen HH J Med Chem; 2002 Nov; 45(23):5150-6. PubMed ID: 12408725 [TBL] [Abstract][Full Text] [Related]
6. 8-Bicycloalkyl-CPFPX derivatives as potent and selective tools for in vivo imaging of the A Humpert S; Schneider D; Bier D; Schulze A; Neumaier F; Neumaier B; Holschbach M Eur J Med Chem; 2024 May; 271():116380. PubMed ID: 38615410 [TBL] [Abstract][Full Text] [Related]
7. In vivo kinetic and steady-state quantification of 18F-CPFPX binding to rat cerebral A1 adenosine receptors: validation by displacement and autoradiographic experiments. Elmenhorst D; Kroll T; Wedekind F; Weisshaupt A; Beer S; Bauer A J Nucl Med; 2013 Aug; 54(8):1411-9. PubMed ID: 23740103 [TBL] [Abstract][Full Text] [Related]
8. 1,3,7-Triethyl-substituted xanthines--possess nanomolar affinity for the adenosine A1 receptor. Van der Walt MM; Terre'Blanche G Bioorg Med Chem; 2015 Oct; 23(20):6641-9. PubMed ID: 26392370 [TBL] [Abstract][Full Text] [Related]
9. Quantification of cerebral A1 adenosine receptors in humans using [18F]CPFPX and PET. Meyer PT; Bier D; Holschbach MH; Boy C; Olsson RA; Coenen HH; Zilles K; Bauer A J Cereb Blood Flow Metab; 2004 Mar; 24(3):323-33. PubMed ID: 15091113 [TBL] [Abstract][Full Text] [Related]
10. Metabolism of the A1 adenosine receptor PET ligand [18F]CPFPX by CYP1A2: implications for bolus/infusion PET studies. Matusch A; Meyer PT; Bier D; Holschbach MH; Woitalla D; Elmenhorst D; Winz OH; Zilles K; Bauer A Nucl Med Biol; 2006 Oct; 33(7):891-8. PubMed ID: 17045169 [TBL] [Abstract][Full Text] [Related]
11. Influence of binding affinity and blood plasma level on cerebral pharmacokinetics and PET imaging characteristics of two novel xanthine PET radioligands for the A Schneider D; Oskamp A; Holschbach M; Neumaier B; Bier D; Bauer A Nucl Med Biol; 2020; 82-83():1-8. PubMed ID: 31838339 [TBL] [Abstract][Full Text] [Related]
12. Caffeine occupancy of human cerebral A1 adenosine receptors: in vivo quantification with 18F-CPFPX and PET. Elmenhorst D; Meyer PT; Matusch A; Winz OH; Bauer A J Nucl Med; 2012 Nov; 53(11):1723-9. PubMed ID: 22966134 [TBL] [Abstract][Full Text] [Related]
13. The role of 5-arylalkylamino- and 5-piperazino- moieties on the 7-aminopyrazolo[4,3-d]pyrimidine core in affecting adenosine A Squarcialupi L; Betti M; Catarzi D; Varano F; Falsini M; Ravani A; Pasquini S; Vincenzi F; Salmaso V; Sturlese M; Varani K; Moro S; Colotta V J Enzyme Inhib Med Chem; 2017 Dec; 32(1):248-263. PubMed ID: 28114825 [TBL] [Abstract][Full Text] [Related]
14. Synthesis of the main metabolite in human blood of the A1 adenosine receptor ligand [18F]CPFPX. Holschbach MH; Bier D; Wutz W; Willbold S; Olsson RA Org Lett; 2009 Oct; 11(19):4266-9. PubMed ID: 19725521 [TBL] [Abstract][Full Text] [Related]
15. Discovery of 1,3-diethyl-7-methyl-8-(phenoxymethyl)-xanthine derivatives as novel adenosine A Harmse R; van der Walt MM; Petzer JP; Terre'Blanche G Bioorg Med Chem Lett; 2016 Dec; 26(24):5951-5955. PubMed ID: 27836398 [TBL] [Abstract][Full Text] [Related]
16. 18F-CPFPX PET identifies changes in cerebral A1 adenosine receptor density caused by glioma invasion. Bauer A; Langen KJ; Bidmon H; Holschbach MH; Weber S; Olsson RA; Coenen HH; Zilles K J Nucl Med; 2005 Mar; 46(3):450-4. PubMed ID: 15750158 [TBL] [Abstract][Full Text] [Related]
17. 5-Substituted 2-benzylidene-1-tetralone analogues as A Janse van Rensburg HD; Terre'Blanche G; van der Walt MM; Legoabe LJ Bioorg Chem; 2017 Oct; 74():251-259. PubMed ID: 28881253 [TBL] [Abstract][Full Text] [Related]
18. Reproducibility of non-invasive a1 adenosine receptor quantification in the rat brain using [(18)F]CPFPX and positron emission tomography. Kroll T; Elmenhorst D; Weisshaupt A; Beer S; Bauer A Mol Imaging Biol; 2014 Oct; 16(5):699-709. PubMed ID: 24595700 [TBL] [Abstract][Full Text] [Related]
19. 7-Amino-2-phenylpyrazolo[4,3-d]pyrimidine derivatives: structural investigations at the 5-position to target human A₁ and A(2A) adenosine receptors. Molecular modeling and pharmacological studies. Squarcialupi L; Colotta V; Catarzi D; Varano F; Betti M; Varani K; Vincenzi F; Borea PA; Porta N; Ciancetta A; Moro S Eur J Med Chem; 2014 Sep; 84():614-27. PubMed ID: 25063944 [TBL] [Abstract][Full Text] [Related]